Abstract
HBV phylogenetics and resistance-associated mutations (RAMs) were surveyed by next-generation sequencing of 21 longitudinal samples from seven patients entering antiviral therapy. The virus populations were dominated by a few abundant lineages that coexisted with substantial numbers of low-frequency variants. A few low-frequency RAMs were observed before treatment, but new ones emerged, and their frequencies increased during therapy. Together, these results support the idea that chronic HBV infection is dominated by a few virus lineages and that an accompanying plethora of diverse, low-frequency variants may function as a reservoir that potentially contribute to viral genetic plasticity, potentially affecting patient outcome.
References
Bimber BN, Dudley DM, Lauck M, Becker EA, Chin EN, Lank SM, Grunenwald HL, Caruccio NC, Maffitt M, Wilson NA, Reed JS, Sosman JM, Tarosso LF, Sanabani S, Kallas EG, Hughes AL, O’Connor DH (2010) Whole-genome characterization of human and simian immunodeficiency virus intrahost diversity by ultradeep pyrosequencing. J Virol 84:12087–12092
Chotiyaputta W, Lok AS (2009) Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 6:453–462
Damerow H, Yuen L, Wiegand J, Walker C, Bock CT, Locarnini S, Tillmann HL (2010) Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol 82:1850–1858
Durantel D (2010) Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied? Antivir Ther 15:521–527
Gong L, Han Y, Chen L, Liu F, Hao P, Sheng J, Li XH, Yu DM, Gong QM, Tian F, Guo XK, Zhang XX (2013) Comparison of next-generation sequencing and clone-based sequencing in analysis of hepatitis B virus reverse transcriptase quasispecies heterogeneity. J Clin Microbiol 51:4087–4094
Guindon S, Gascuel O (2003) A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 52:696–704
Jia S, Wang F, Li F, Chang K, Yang S, Zhang K, Jiang W, Shang Y, Deng S, Chen M (2014) Rapid detection of hepatitis B virus variants associated with lamivudine and adefovir resistance by multiplex ligation-dependent probe amplification combined with real-time PCR. J Clin Microbiol 52:460–466
Jones LR, Sede M, Manrique JM, Quarleri J (2016) Virus evolution during chronic hepatitis B virus infection as revealed by ultradeep sequencing data. J Gen Virol 97:435–444
Khudyakov Y (2010) Coevolution and HBV drug resistance. Antivir Ther 15:505–515
Liu BM, Li T, Xu J, Li XG, Dong JP, Yan P, Yang JX, Yan L, Gao ZY, Li WP, Sun XW, Wang YH, Jiao XJ, Hou CS, Zhuang H (2010) Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naive Chinese patients. Antiviral Res 85:512–519
Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, Wang C, Holmes SP, Babrzadeh F, Gharizadeh B, Hanczaruk B, Simen BB, Egholm M, Shafer RW (2009) Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis 199:1275–1285
Mirandola S, Sebastiani G, Rossi C, Velo E, Erne EM, Vario A, Tempesta D, Romualdi C, Campagnolo D, Alberti A (2012) Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy. Antiviral Res 96:422–429
Noguchi C, Imamura M, Tsuge M, Hiraga N, Mori N, Miki D, Kimura T, Takahashi S, Fujimoto Y, Ochi H, Abe H, Maekawa T, Tateno C, Yoshizato K, Chayama K (2009) G-to-A hypermutation in hepatitis B virus (HBV) and clinical course of patients with chronic HBV infection. J Infect Dis 199:1599–1607
Nylander JAA (2004) MrAIC.pl. Program distributed by the author. Evolutionary Biology Centre, Uppsala University
Rodriguez C, Chevaliez S, Bensadoun P, Pawlotsky JM (2013) Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. Hepatology 58:890–901
Schloss PD, Gevers D, Westcott SL (2011) Reducing the effects of PCR amplification and sequencing artifacts on 16S rRNA-based studies. PLoS One 6:e27310
Schmieder R, Edwards R (2011) Quality control and preprocessing of metagenomic datasets. Bioinformatics 27:863–864
Shendure J, Ji H (2008) Next-generation DNA sequencing. Nat Biotechnol 26:1135–1145
Skums P, Dimitrova Z, Campo DS, Vaughan G, Rossi L, Forbi JC, Yokosawa J, Zelikovsky A, Khudyakov Y (2012) Efficient error correction for next-generation sequencing of viral amplicons. BMC Bioinform 13(Suppl 10):S6
Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, Capobianchi MR (2009) Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol 83:1718–1726
Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF (2001) Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33:751–757
Wang YJ, Yang L, Zuo JP (2016) Recent developments in antivirals against hepatitis B virus. Virus Res 213:205–213
Zhou B, Dong H, He Y, Sun J, Jin W, Xie Q, Fan R, Wang M, Li R, Chen Y, Xie S, Shen Y, Huang X, Wang S, Lu F, Jia J, Zhuang H, Locarnini S, Zhao GP, Jin L, Hou J (2015) Composition and interactions of hepatitis B virus quasispecies defined the virological response during telbivudine therapy. Sci Rep 5:17123
Zoulim F, Locarnini S (2009) Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137(1593–1608):e1591–e1592
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This work was supported by the Argentinean National Agency of Scientific and Technological Promotion (grant number PICT 2012-0422 to JQ and PICT PRH-14 120 to LRJ); the University of Buenos Aires (grant number 20020110100034); and the Argentinean National Scientific and Technical Research Council (grant number PIP-11220110101089).
Conflict of interest
All authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in this study were in accordance with the ethical standards of the institution and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Huesped Foundation Ethics Committee, Buenos Aires, Argentina, and informed consent was obtained from each patient.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Jones, L.R., Sede, M., Manrique, J.M. et al. Hepatitis B virus resistance substitutions: long-term analysis by next-generation sequencing. Arch Virol 161, 2885–2891 (2016). https://doi.org/10.1007/s00705-016-2959-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00705-016-2959-8